Clinical Trial Update: Cx611-0101, eASCs Intravenous Administration to Refractory Rheumatoid Arthritis Patients [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial update for Cx611-0101 using intravenous eASCs in patients with refractory rheumatoid arthritis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Cx611-0101

Snippet

Sponsor: Tigenix S.A.U. | Conditions: Rheumatoid Arthritis Aggravated | Phase 1, Phase 2 | Status: COMPLETED